Global Microbiome Therapeutics Market Research Report 2018

  • ID:PD023558
  • January 2018
  • QY Research
                          

The Global Microbiome Therapeutics market research report is the study prepared by analysts, which contain a detailed analysis of drivers, restraints, and opportunities along with their impact on the Microbiome Therapeutics market growth. This research report will assist in being relevant and future-oriented, while improving decision-making capabilities and reducing market risk. It is an excellent way to find the best market or target demographic for a product or service.

The report gives detailed overview of the products and segments the market as per application/ type/ regions/ end user (as applicable). The study evaluates the global market on the basis of current and past sales, revenue, capacity, and production status. The future outlook and prospects are then derived with the help of industry experts.

Furthermore, the research report also helps to understand the comprehensive profiles of the key players in the market and in-depth view of the competitive landscape worldwide.

This report studies the Microbiome Therapeutics market status and outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, and splits the Microbiome Therapeutics market by product type and applications/end industries.

In the last several years, global market of microbiome therapeutics developed rapidly, with an average growth rate of 98%. In 2017, global market size of microbiome therapeutics is nearly 14 M USD.

For developing product, there are 2 products in Phase 3, 7 products in Phase 2, 8 products in Phase 1 and 17 products in Preclinical. The total investment for Microbiome Therapeutics developing is around 293 M USD in 2017.

The major players in global Microbiome Therapeutics market include 

  • Seres Therapeutics
  • Assembly Biosciences
  • Synthetic Biologics
  • Interxon
  • PureTech
  • Synlogic
  • Enterome BioScience
  • 4D Pharma
  • Second Genome
  • AOBiome
  • C3 Jian
  • Rebiotix
  • MicroBiome Therapeutics LLC
  • Metabiomics
  • Ritter Pharmaceuticals
  • Symberix
  • OpenBiome
  • Azitra
  • Symbiotix Biotherapies
  • Osel
  • Metabogen

Geographically, this report is segmented into several key regions, with market size and R&D investment of microbiome therapeutics in these regions, from 2012 to 2025 (forecast), covering
  • North America
  • Europe
  • Asia Pacific
  • Other

On the basis on the end users/applications, this report covers 
  • C. difficile Infection (CDI)
  • Inflammatory Bowel Disease (IBD)
  • Orphan Drug 
  • Immuno-oncology
  • Others

Table of Contents - Snapshot
1 Industry Overview
2 Global Industry Competition by Manufacturers
3 Global Industry Capacity, Production, Revenue (Value) by Region (2013-2018)
4 Global Industry Supply (Production), Consumption, Export, Import by Region (2013-2018)
5 Global Industry Production, Revenue (Value), Price Trend by Type
6 Global Industry Analysis by Application
7 Global Industry Manufacturers Profiles/Analysis
8 Industry Manufacturing Cost Analysis
9 Industrial Chain, Sourcing Strategy and Downstream Buyers
10 Marketing Strategy Analysis, Distributors/Traders
11 Market Effect Factors Analysis
12 Global Industry Forecast (2018-2025)
13 Research Findings and Conclusion
14 Appendix

Table of Contents - Guidelines
 
1 Microbiome Therapeutics Market Overview    1
1.1 Microbiome Therapeutics Product Overview               1
1.2 Microbiome Therapeutics Segment by Application    2
1.2.1 Global Microbiome Therapeutics R&D Investment and Growth Rate Comparison by Application (2012-2022)             2
1.2.2 Global Microbiome Therapeutics R&D Investment Market Share by Types in 2016  4
1.2.3 C. difficile Infection (CDI)   5
1.2.4 Inflammatory Bowel Disease (IBD)                5
1.2.5 Orphan Drug           6
1.2.6 Immuno-oncology                6
1.3 Microbiome Therapeutics Market by Pipeline              6
1.4 Global Microbiome Therapeutics Market by Regions (2012-2022)       9
1.4.1 Global Microbiome Therapeutics Market Size and Growth Rate Comparison by Regions (2012-2022)              9
1.4.2 North America Microbiome Therapeutics Status and Prospect (2012-2025) 10
1.4.3 Asia Pacific Microbiome Therapeutics Status and Prospect (2012-2025)        11
1.4.4 Europe Microbiome Therapeutics Status and Prospect (2012-2025)                12
1.5 Global Microbiome Therapeutics Market Size (2012-2025)     13
2 Global Microbiome Therapeutics Market Competition by Manufacturers/Brand             14
2.1 Global Microbiome Therapeutics Sales and Share by Manufacturers 14
2.2 Global Microbiome Therapeutics R&D Investment and Share by Manufacturers (2012-2017) 16
2.3 Manufacturers Microbiome Therapeutics Headquarters, Established Date, Product Types     19
2.4 Microbiome Therapeutics Market Competitive Situation and Trends                21
2.4.1 Microbiome Therapeutics R&D Investment Concentration Rate      21
2.4.2 Microbiome Therapeutics R&D Investment Share of Top 3 and Top 5 Manufacturers             22
2.4.3 Mergers & Acquisitions, Expansion               23
3 Global Microbiome Therapeutics R&D Investment by Regions (2012-2017)        25
3.1 Global Microbiome Therapeutics Developer Distribution by Regions 25
3.2 Global Microbiome Therapeutics R&D Investment and Market Share by Regions (2012-2017)               26
3.3 Global Microbiome Therapeutics R&D Investment and Growth Rate (2012-2017)        28
3.4 North America Microbiome Therapeutics R&D Investment and Growth Rate (2012-2017)       29
3.5 Europe Microbiome Therapeutics R&D Investment and Growth Rate (2012-2017)      30
4 Global Microbiome Therapeutics Market Size by Regions (2012-2025)  31
4.1 Global Microbiome Therapeutics Consumption by Regions (2012-2025)           31
4.2 North America Microbiome Therapeutics Market Size (2012-2025)     34
4.3 Europe Microbiome Therapeutics Market Size (2012-2025)    35
4.4 Asia Pacific Microbiome Therapeutics Market Size (2012-2025)            36
5 Global Microbiome Therapeutics R&D Investment by Application          37
5.1 Global Major Microbiome Therapeutics Developer Application            37
5.2 Global Microbiome Therapeutics Investment by Application (2012-2017)        39
5.3 Global Microbiome Therapeutics Production Growth by Application (2012-2017)         41
6 Microbiome Therapeutics Market Analysis by Product Pipeline               42
6.1 Microbiome Therapeutics Market by Pipeline              42
6.2 Microbiome Therapeutics Product Introduction          43
6.2.1 Phase 3 Product Introduction          43
6.2.1.1 SER-109  44
6.2.1.2 RBX2660                44
6.2.1.3 RP-G28   44
6.2.2 Phase 2 Product Introduction          44
6.2.2.1 ribaxamase          45
6.2.2.2 SYN-010 45
6.2.2.3 EB8018   45
6.2.2.4 SGM-1019             45
6.2.2.5 Ammonia Oxidizing Bacteria (AOB)            46
6.2.2.6 C16G2     46
6.2.2.7 LACTIN-V              47
6.2.2.8 CBM588 48
6.2.3 Phase 1 Product Introduction          48
6.2.3.1 SER-262  49
6.2.3.2 SER-287  49
6.2.3.3 ABI-H0731             49
6.2.3.4 Gemicel 50
6.2.3.5 AG014    50
6.2.3.6 VE303     51
6.2.3.7 Blautix    51
6.2.3.8 RBX2660                52
6.2.3.9 RBX7455                52
7 Analysis  Industry Key Manufacturers 53
7.1 Seres Therapeutics  53
7.1.1 Company Profile    53
7.1.2 Product Information            54
7.1.3 Investment and Investment of R&D             55
7.2 Assembly Biosciences             55
7.2.1 Company Profile    55
7.2.2 Product Information            56
7.2.3 Investment and Investment of R&D             57
7.3 Synthetic Biologics    58
7.3.1 Company Profile    58
7.3.2 Product Information            59
7.3.3 Investment and Investment of R&D             60
7.4 Interxon       60
7.4.1 Company Profile    60
7.4.2 Product Information            61
7.4.3 Investment and Investment of R&D             62
7.5 PureTech      62
7.5.1 Company Profile    62
7.5.2 Product Information            63
7.5.3 Investment and Investment of R&D             64
7.6 Synlogic         64
7.6.1 Company Profile    64
7.6.2 Product Information            65
7.6.3 Investment and Investment of R&D             66
7.7 Enterome BioScience              66
7.7.1 Company Profile    66
7.7.2 Product Information            67
7.7.3 Investment and Investment of R&D             68
7.8 4D Pharma   69
7.8.1 Company Profile    69
7.8.2 Product Information            71
7.8.3 Investment and Investment of R&D             72
7.9 Second Genome       72
7.9.1 Company Profile    72
7.9.2 Product Information            74
7.9.3 Investment and Investment of R&D             75
7.10 AOBiome   75
7.10.1 Company Profile 75
7.10.2 Product Information          76
7.10.3 Investment and Investment of R&D           77
7.11 C3 Jian         77
7.11.1 Company Profile 77
7.11.2 Product Information          78
7.11.3 Investment and Investment of R&D           78
7.12 Rebiotix      79
7.12.1 Company Profile 79
7.12.2 Product Information          80
7.12.3 Investment and Investment of R&D           80
7.13 MicroBiome Therapeutics LLC           81
7.13.1 Company Profile 81
7.13.2 Product Information          82
7.13.3 Investment and Investment of R&D           82
7.14 Metabiomics            83
7.14.1 Company Profile 83
7.14.2 Product Information          84
7.14.3 Investment and Investment of R&D           85
7.15 Ritter Pharmaceuticals         85
7.15.1 Company Profile 85
7.15.2 Product Information          86
7.15.3 Investment and Investment of R&D           87
7.16 Symberix    87
7.16.1 Company Profile 87
7.16.2 Product Information          88
7.16.3 Investment and Investment of R&D           88
7.17 OpenBiome              89
7.16.1 Company Profile 89
7.16.2 Product Information          90
7.16.3 Investment and Investment of R&D           90
7.18 Azitra           91
7.18.1 Company Profile 91
7.18.2 Product Information          92
7.18.3 Investment and Investment of R&D           92
7.19 Symbiotix Biotherapies        93
7.19.1 Company Profile 93
7.19.2 Product Information          94
7.19.3 Investment and Investment of R&D           95
7.20 Osel              95
7.20.1 Company Profile 95
7.20.2 Product Information          96
7.20.3 Investment and Investment of R&D           97
7.21 Metabogen               98
7.21.1 Company Profile 98
7.21.2 Product Information          99
7.21.3 Investment and Investment of R&D           99
8 Microbiome Therapeutics Manufacturing Cost Analysis              100
8.1 Microbiome Therapeutics R&D Cost Analysis                100
8.1.1Clinical Phase Costs               101
8.1.2 Capitalized Costs   102
8.2 Proportion of Manufacturing Cost Structure 103
8.2.1 Raw Materials         103
8.2.2 Labor Cost Analysis               105
8.2.2.1 USA Labor Cost Analysis 105
8.2.2.2 Europe Labor Costs Analysis         106
8.2.2.3 Asia Labor Costs Analysis                108
8.2.3 Other Costs Analysis            109
8.2.3.1 USA Cost of Electricity Analysis    109
8.2.3.2 USA Water Cost Analysis                109
8.2.3.3 Europe Cost of Electricity Analysis              110
8.2.3.4 Europe Water Cost Analysis          111
8.2.3.5 China Cost of Electricity Analysis 112
8.2.3.6 China Water Cost Analysis             113
8.2.4 Manufacturing Expenses   113
8.3 Manufacturing Process Analysis         114
9 Industrial Chain, Sourcing Strategy and Downstream Buyers     115
9.1 Microbiome Therapeutics Industrial Chain Analysis   115
9.2 Upstream Raw Materials Sourcing     116
9.3 Downstream Buyers                116
10 Marketing Strategy Analysis, Distributors/Traders       119
10.1 Marketing Channel                119
10.1.1 Direct Marketing 119
10.1.2 Indirect Marketing             119
10.1.3 Marketing Channel Development Trend  120
10.2 Market Positioning                120
10.2.1 Pricing Strategy    120
10.2.2 Brand Strategy     121
10.2.3 Target Client         123
10.3 Distributors/Traders List      123
11 Market Effect Factors Analysis             125
11.1 Technology Progress             125
11.2 Consumer Needs/Customer Preference Change     126
11.3 Economic/Political Environmental Change   126
12 Global Microbiome Therapeutics Market Forecast (2017-2022)             135
12.1 Global Microbiome Therapeutics R&D Investment and Market Size Forecast              135
12.1.1 Global Microbiome Therapeutics R&D Investment and Growth Rate Forecast (2017-2022)                135
12.1.2 Global Microbiome Therapeutics Market Size and Growth Rate Forecast (2017-2025)         136
12.2 Global Microbiome Therapeutics R&D Investment Forecast by Regions (2017-2022)                136
12.2.1 North America Microbiome Therapeutics R&D Investment Forecast (2017-2022)   138
12.2.2 Europe Microbiome Therapeutics R&D Investment Forecast (2017-2022)  139
12.3 Global Microbiome Therapeutics Market Size Forecast by Regions (2018-2025)          139
12.3.1 North America Microbiome Therapeutics Market Size Forecast (2018-2025)            141
12.3.2 Europe Microbiome Therapeutics Market Size Forecast (2018-2025)           142
12.3.3 Asia Pacific Microbiome Therapeutics Market Size Forecast (2018-2025)    143
12.4 Global Microbiome Therapeutics R&D Investment Forecast by Application (2017-2022)         143
12.5 Global Microbiome Therapeutics Market Size Forecast by Application (2018-2025)   144
13 Research Findings and Conclusion      146
14 Methodology and Data Source             147
14.1 Methodology/Research Approach  147
14.1.1 Research Programs/Design            147
14.1.2 Market Size Estimation     148
14.1.3 Market Breakdown and Data Triangulation             149
14.2 Data Source              150
14.2.1 Secondary Sources             150
14.2.2 Primary Sources  151
14.3 Disclaimer  152
14.4 Author List 153
 
List of Tables and Figures
 
Figure Product Picture of Microbiome Therapeutics         2
Table Application of Microbiome Therapeutics   2
Table Global Microbiome Therapeutics R&D Investment (K USD) and Growth Rate Comparison by Types (2012-2022)      3
Figure Global Microbiome Therapeutics R&D Investment Market Share by Types in 2016               4
Figure C. difficile Infection (CDI) Examples            5
Figure Inflammatory Bowel Disease (IBD) Examples         5
Figure Orphan Drug Examples    6
Figure Immuno-oncology Examples         6
Table Microbiome Therapeutics Market by Pipeline         6
Figure Global Microbiome Therapeutics Market Size (M USD) Comparison and Growth Rate by Regions (2012-2025)        9
Table Microbiome Therapeutics Market Size (M USD) Comparison by Regions (2012-2025)            9
Figure North America Microbiome Therapeutics Market Size (M USD) and Growth Rate (2012-2025)        10
Figure Asia Pacific Microbiome Therapeutics Revenue (M USD) and Growth Rate (2012-2025)     11
Figure Europe Microbiome Therapeutics Revenue (M USD) and Growth Rate (2012-2025)             12
Figure Global Microbiome Therapeutics Market Size (M USD) Status and Outlook (2012-2025)     13
Table Global Microbiome Therapeutics Pipeline of Key Manufacturers in 2017    14
Table Global Microbiome Therapeutics R&D Investment (K USD) of Key Manufacturers (2016-2017)         16
Table Global Microbiome Therapeutics R&D Investment Share by Manufacturers (2016-2017)     16
Figure 2016 Microbiome Therapeutics R&D Investment Share by Manufacturers               18
Figure 2017 Microbiome Therapeutics R&D Investment Share by Manufacturers               19
Table Manufacturers Microbiome Therapeutics Headquarters and Established Date        19
Table Manufacturers Microbiome Therapeutics Product Category            20
Figure 2016 Microbiome Therapeutics R&D Investment Share by Manufacturers               21
Figure Microbiome Therapeutics R&D Investment Share of Top 3 Manufacturers              22
Figure Microbiome Therapeutics R&D Investment Share of Top 5 Manufacturers              23
Table Mergers & Acquisitions, Expansion              23
Table Global Microbiome Therapeutics Developer Distribution by Regions in 2017             25
Figure Global Microbiome Therapeutics Developer Distribution by Regions          26
Table Global Microbiome Therapeutics R&D Investment (K USD) by Regions (2012-2017)               26
Table Global Microbiome Therapeutics R&D Investment Market Share by Regions (2012-2017)   26
Figure Global Microbiome Therapeutics R&D Investment Market Share by Regions (2012-2017) 27
Figure 2016 Global Microbiome Therapeutics R&D Investment Market Share by Regions                27
Figure Global Microbiome Therapeutics R&D Investment (K USD) and Growth Rate (2012-2017) 28
Figure North America Microbiome Therapeutics R&D Investment (K USD) and Growth Rate (2012-2017)                29
Figure Europe Microbiome Therapeutics R&D Investment (K USD) and Growth Rate (2012-2017)               30
Table Global Microbiome Therapeutics Market Size (M USD) by Regions (2012-2018)       31
Table Global Microbiome Therapeutics Market Size (M USD) by Regions (2019-2025)       31
Table Global Microbiome Therapeutics Consumption Market Share by Regions (2012-2018)         31
Table Global Microbiome Therapeutics Consumption Market Share by Regions (2019-2025)         32
Figure Global Microbiome Therapeutics Consumption Market Share by Regions (2012-2025)        32
Figure 2025 Global Microbiome Therapeutics Consumption Market Share by Regions      33
Figure North America Microbiome Therapeutics Market Size (M USD) and Growth Rate (2012-2025)        34
Figure Europe Microbiome Therapeutics Market Size (M USD) and Growth Rate (2012-2025)       35
Figure Asia Pacific Microbiome Therapeutics Market Size (M USD) and Growth Rate (2012-2025)                36
Table Global Major Microbiome Therapeutics Developer Application       37
Table Global Microbiome Therapeutics R&D Investment (K USD) by Application (2012-2017)        39
Table Global Microbiome Therapeutics R&D Investment Share by Application (2012-2017)            39
Figure R&D Investment Market Share of Microbiome Therapeutics by Application (2012-2017)   40
Figure 2016 R&D Investment Market Share of Microbiome Therapeutics by Application  40
Figure Global Microbiome Therapeutics R&D Investment Growth by Application (2012-2017)       41
Table Global Microbiome Therapeutics Market by Pipeline           42
Table Phase 3 Product Introduction         43
Table Phase 2 Product Introduction         44
Figure Ammonia Oxidizing Bacteria (AOB) Pipeline           46
Figure LACTIN-V Pipeline              47
Figure CBM588 Pipeline                48
Table Phase 1 Product Introduction         48
Figure SER-262 Pipeline 49
Figure ABI-H0731 Pipeline            49
Figure Gemicel Pipeline                50
Figure VE303 Pipeline     51
Figure Blautix Pipeline   51
Figure RBX2660 Pipeline                52
Figure RBX7455 Pipeline                52
Table Seres Therapeutics Company Profile           53
Table Microbiome Therapeutics Product Information of Seres Therapeutics         54
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Seres Therapeutics (2016 and 2017)     55
Table Assembly Biosciences Company Profile     55
Table Microbiome Therapeutics Product Information of Assembly Biosciences   56
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Assembly Biosciences (2016 and 2017)        57
Table Synthetic Biologics Company Profile            58
Table Microbiome Therapeutics Product Information of Synthetic Biologics          59
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Synthetic Biologics (2016 and 2017)              60
Table Interxon Company Profile                60
Table Microbiome Therapeutics Product Information of Interxon              61
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Interxon (2016 and 2017)            62
Table PureTech Company Profile              62
Table Microbiome Therapeutics Product Information of PureTech            63
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of PureTech (2016 and 2017)            64
Table Synlogic Company Profile 64
Table Microbiome Therapeutics Product Information of Synlogic               65
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Synlogic (2016 and 2017)            66
Table Enterome BioScience Company Profile      66
Table Microbiome Therapeutics Product Information of Enterome BioScience    67
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Enterome BioScience (2016 and 2017)          68
Table 4D Pharma Company Profile           69
Table Microbiome Therapeutics Product Information of 4D Pharma         71
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of 4D Pharma (2016 and 2017)            72
Table Second Genome Company Profile               72
Table Microbiome Therapeutics Product Information of Second Genome             74
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Second Genome (2016 and 2017)                75
Table AOBiome Company Profile              75
Table Microbiome Therapeutics Product Information of AOBiome            76
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of AOBiome (2016 and 2017)            77
Table C3 Jian Company Profile    77
Table Microbiome Therapeutics Product Information of C3 Jian  78
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of C3 Jian (2016 and 2017)            78
Table Rebiotix Company Profile 79
Table Microbiome Therapeutics Product Information of Rebiotix               80
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Rebiotix (2016 and 2017)            80
Table MicroBiome Therapeutics LLC Company Profile      81
Table Microbiome Therapeutics Product Information of MicroBiome Therapeutics LLC    82
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of MicroBiome Therapeutics LLC (2016 and 2017)             82
Table Metabiomics Company Profile       83
Table Microbiome Therapeutics Product Information of Metabiomics     84
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Metabiomics (2016 and 2017)                85
Table Ritter Pharmaceuticals Company Profile    85
Table Microbiome Therapeutics Product Information of Ritter Pharmaceuticals  86
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Ritter Pharmaceuticals (2016 and 2017)              87
Table Symberix Company Profile              87
Table Microbiome Therapeutics Product Information of Symberix            88
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Symberix (2016 and 2017)            88
Table OpenBiome Company Profile         89
Table Microbiome Therapeutics Product Information of OpenBiome       90
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of OpenBiome (2016 and 2017)                90
Table Azitra Company Profile      91
Table Microbiome Therapeutics Product Information of Azitra    92
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Azitra (2016 and 2017)     92
Table Symbiotix Biotherapies Company Profile   93
Table Microbiome Therapeutics Product Information of Symbiotix Biotherapies 94
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Symbiotix Biotherapies (2016 and 2017)      95
Table Osel Company Profile        95
Table Microbiome Therapeutics Product Information of Osel      96
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Osel (2016 and 2017)     97
Table Metabogen Company Profile         98
Table Microbiome Therapeutics Product Information of Metabogen       99
Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Metabogen (2016 and 2017)                99
Figure typical phases from research to the market for a drug candidate  101
Table Out-of-pocket Preclinical and Clinical Period Cost per Investigational Biopharmaceutical Compound             102
Table Capitalized Preclinical and Clinical Period costs per Investigational Biopharmaceutical Compound   103
Figure Manufacturing Cost Structure of Microbiome Therapeutics            103
Figure Assessment of API Manufacturing Cost By Region              104
Figure USA Labor Cost Analysis 2012-2016             105
Figure Cost of Employing a Factory Worker          106
Figure 2016 Estimated Labour Costs for the Whole Economy in Europe   107
Figure Monthly Minimum Wages in Asia 2016     108
Figure China Labor Costs 2013-2016         108
Table Average Price of Electricity to Ultimate Customers 2007-2016          109
Figure Electricity Prices for Household Consumers in 2016             110
Figure Summary of the Driving Assumptions       112
Figure Industrial Electric Rates 2016 (PER KWH)  112
Figure Manufacturing Process Analysis of Microbiome Therapeutics        114
Figure Microbiome Therapeutics Industrial Chain Analysis             115
Table Major Buyers of Microbiome Therapeutics              116
Figure Setting Pricing Policy         121
Table Distributors/Traders List   123
Table Predominant Bacterial Phyla in the Human Body   125
Figure Global GDP Growth Rate for 2016               127
Figure US GDP 2006-2016 (Billion USD)   128
Figure US CPI Change 2016-2017               128
Figure EU GDP 2006-2016 (Billion USD)   129
Figure EU CPI Change 2012-2016               129
Figure Germany GDP 2006-2016 (Billion USD)      130
Figure Germany CPI Change 2016-2017  130
Figure UK GDP 2006-2016 (Billion USD)   130
Figure UK CPI Change 2016-2017               131
Figure Italy GDP 2006-2016 (Billion USD)                131
Figure Italy CPI Change 2016-2017            132
Figure Japan GDP 2006-2016 (Billion USD)             132
Figure Japan CPI Change 2012-2016         133
Figure China GDP 2006-2016 (Billion USD)              133
Figure China CPI Change 2016-2017          134
Figure Global Microbiome Therapeutics R&D Investment (K USD) and Growth Rate Forecast (2017-2022)              135
Figure Global Microbiome Therapeutics Market Size (M USD) and Growth Rate Forecast (2017-2025)      136
Table Global Microbiome Therapeutics R&D Investment (K USD) Forecast by Regions (2017-2022)             136
Figure Global Microbiome Therapeutics R&D Investment Market Share Forecast by Regions (2017-2022)               137
Figure North America Microbiome Therapeutics R&D Investment (K USD) and Growth Rate Forecast (2017-2022)              138
Figure Europe Microbiome Therapeutics R&D Investment (K USD) and Growth Rate Forecast (2017-2022)             139
Table Global Microbiome Therapeutics Market Size (M USD) Forecast by Regions (2018-2025)     139
Figure Global Microbiome Therapeutics Market Size Share Forecast by Regions (2018-2025)         140
Figure North America Microbiome Therapeutics Market Size (M USD) and Growth Rate Forecast (2018-2025)      141
Figure Europe Microbiome Therapeutics Market Size (M USD) and Growth Rate Forecast (2018-2025)     142
Figure Asia Pacific Microbiome Therapeutics Market Size (M USD) and Growth Rate Forecast (2018-2025)             143
Table Global Microbiome Therapeutics R&D Investment (K USD) Forecast by Application (2017-2022)      143
Figure Global Microbiome Therapeutics R&D Investment Share Forecast by Type (2017-2022)     144
Table Global Microbiome Therapeutics Market Size (M USD) Forecast by Application (2018-2025)              144
Figure Global Microbiome Therapeutics Consumption Forecast by Application (2018-2025)           145
Table Research Programs/Design for This Report              147
Figure Bottom-up and Top-down Approaches for This Report     149
Figure Data Triangulation              150
Table Key Data Information from Secondary Sources      151
Table Key Data Information from Primary Sources            152
 

Related Reports
Global Population Health Management Market Research Report 2017

The Global Population Health Management Market Research Report provides a detailed market overview along with the analysis of industry’s gross  read more..


Global Water Distiller Market Insights, Forecast to 2025

Water Distiller Market Research Report offered by DecisionDatabases.com provides a detailed study on the industrial development of the market under the  read more..


EMEA (Europe, Middle East and Africa) Hepatitis A Vaccine Market Report 2017

The EMEA (Europe, Middle East and Africa) Hepatitis A Vaccine Market Research Report provides a detailed market overview along with the analysis of  read more..


Global Health Insurance Market Report 2019-2025

The Health Insurance market report is a recent research added by DecisionDatabases.com, offers critical insight into the Market dynamic. This report also  read more..


Global Boat First Aid Kits Industry 2016 Market Research Report

The Global Boat First Aid Kits Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Boat First Aid Kits  read more..


Global Facial Aesthetics Market Report 2018-2025

The Global Facial Aesthetics Market report is a recent research added by DecisionDatabases.com, offers critical insight into the market dynamic. This  read more..


Global Spinal Fixation Systems Market Research Report 2017

The Global Spinal Fixation Systems Market Research Report provides a detailed market overview along with the analysis of industry’s gross margin,  read more..


Global Vascular Graft Market Insights, Forecast to 2025

Vascular Graft Market Research Report offered by DecisionDatabases.com provides a detailed study on the industrial development of the market under the  read more..


Global Blood Products Market Insights, Forecast to 2025

Blood Products Market Research Report offered by DecisionDatabases.com provides a detailed study on the industrial development of the market under the  read more..


Global Nateglinide Market Research Report 2021

The Global Nateglinide Market Research Report provides a detailed market overview along with the analysis of industry’s gross margin, cost  read more..